Initiated pre-clinical trials for the use of PCI in the treatment of Bladder Cancer

Posted on Dec 3, 2009

Oslo, 3 December 2009 – PCI Biotech has initiated pre-clinical trials for the use of Photochemical Internalisation (PCI) in the treatment of Bladder cancer. The pre-clinical trials will be concluded during the first half of 2010, and a phase I/II study (first in man) is expected to start during 2010. Bladder cancer is a very interesting disease area […]

Successful completion of the first dose group in the Phase I/II study of Amphinex® in cancer patients

Posted on Oct 19, 2009

Oslo, 19 October 2009 – PCI Biotech has completed the treatment of the first dose group in the phase I/II study of Amphinex® in cancer patients. No serious adverse events have been recorded and tumour response was seen even at this low dose. The study is primarily enrolling Head & Neck cancer patients and is […]

First cancer patient included in PCI Biotech’s Phase I/II trial of Amphinex®

Posted on Aug 24, 2009

Oslo, 24 August 2009 – PCI Biotech Holding ASA today announced that the first cancer patient has received treatment in the Phase I/II trial with the lead candidate Amphinex®, used in PCI Biotech’s unique technology for targeted enhancement of therapeutics in cancer treatment. The patient was treated at the University College Hospital (UCH) in London. […]